Sam Altman's longevity startup is upping the dose in an Alzheimer's drug trial after a lackluster first round
- Alzheimer: 2 events in the last 90 days
- Previous: 2 days earlier · FDA clears blood test to aid evaluation for Alzheimer's disease
What happened
The Sam Altman-backed longevity biotech company is upping the dose of its experimental Alzheimer's drug in clinical trials.
Summary assembled by rule from the sources below